--- title: "Revelation Biosciences (REVB) news: reverse split and offering" url: "https://aibio.space/companies/revelation-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "REVB reverse split, offering and Nasdaq notice news: Nasdaq panel keeps Revelation Biosciences listed on condition of reverse stock split." --- REVB Revelation Biosciences, Inc. NASDAQ · United States # Revelation Biosciences (REVB) news REVB reverse split, offering and Nasdaq notice news Company Updates · 2026-08-17 ## [Revelation grants CEO and CFO restricted stock tied to market value](https://aibio.space/news/revelation-grants-ceo-cfo-restricted-stock-tied-market-value/) James Rolke and Chester Zygmont each received restricted stock awards that vest in four tranches tied to market capitalization milestones of $30 million to $120 million. ## Latest Revelation Biosciences news 1. 2026-08-06 Company Updates [Revelation reports second quarter 2026 results and cash into early 2027](https://aibio.space/news/revelation-reports-second-quarter-2026-results-cash-early-2027/) Revelation reported a net loss of $3.3 million for the quarter and $11.5 million in cash at June 30, 2026, which it says can fund operations through the first quarter of 2027. 2. 2026-07-10 Company Updates [Revelation adopts stockholder rights plan with a 10% trigger](https://aibio.space/news/revelation-adopts-stockholder-rights-plan-10-percent-trigger/) The board adopted a rights plan on July 10, 2026 and declared a dividend of one right per share, payable to stockholders of record on July 21, 2026. 3. 2026-06-24 Company Updates [Revelation amends CEO and CFO employment agreements and bylaws](https://aibio.space/news/revelation-amends-ceo-cfo-employment-agreements-bylaws/) The amended agreements raise change-in-control severance and set a three-year initial term, and the board amended the bylaws on proxy nominations, the definition of Cause and emergency succession. 4. 2026-05-07 Company Updates [Revelation Biosciences reports first quarter 2026 net loss of $3.0 million](https://aibio.space/news/revelation-biosciences-reports-first-quarter-2026-net-loss-3-0-million/) Cash stood at $14.1 million on March 31, 2026, which the company says covers operations through the first quarter of 2027. 5. 2025-09-15 Financings [Revelation Biosciences gets $9.6 million gross proceeds in warrant inducement deal](https://aibio.space/news/revelation-biosciences-gets-9-6-million-gross-proceeds-warrant/) Holders of 13,065,000 Class H warrants agreed to exercise at $2.20 per share and receive 13,065,000 new Class I warrants in a private placement. Roth Capital Partners advised. 6. 2025-09-15 Financings [Revelation Biosciences agrees $9.6 million immediate warrant exercise](https://aibio.space/news/revelation-biosciences-agrees-9-6-million-immediate-warrant-exercise/) Revelation Biosciences said on September 11, 2025 that holders will exercise warrants for up to 4,355,000 shares at $2.20 each, about $9.6 million in gross proceeds. In return they receive new Class I warrants for up to 13,065,000 shares, which cannot be exercised until stockholders approve them. 7. 2025-01-07 Listings [Nasdaq panel keeps Revelation Biosciences listed on condition of reverse stock split](https://aibio.space/news/nasdaq-panel-keeps-revelation-biosciences-listed-condition-reverse/) The Nasdaq Hearings Panel kept the stock listed on two conditions: a reverse stock split by January 31, 2025 and a $1.00 close for ten straight trading days by February 14, 2025. The panel confirmed the equity deficiency is cured. ## Revelation Biosciences at a glance - **Ticker**: REVB - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $11.5 million ### Related companies - [CLARITAS PHARMACEUTICALS INC.](https://aibio.space/companies/claritas-pharmaceuticals/) OTC: CLAZF - [Iovance Biotherapeutics](https://aibio.space/companies/iovance-biotherapeutics/) NASDAQ: IOVA - [CG Oncology](https://aibio.space/companies/cg-oncology/) NASDAQ: CGON - [Curis](https://aibio.space/companies/curis/) NASDAQ: CRIS - [Benitec Biopharma](https://aibio.space/companies/benitec-biopharma/) NASDAQ: BNTC - [BridgeBio Pharma](https://aibio.space/companies/bridgebio-pharma/) NASDAQ: BBIO - [Unicycive Therapeutics](https://aibio.space/companies/unicycive-therapeutics/) NASDAQ: UNCY - [eFFECTOR Therapeutics](https://aibio.space/companies/effector-therapeutics/) OTC: EFTR ### Also on NASDAQ - [Nuvectis Pharma](https://aibio.space/companies/nuvectis-pharma/) NVCT - [Iovance Biotherapeutics](https://aibio.space/companies/iovance-biotherapeutics/) IOVA - [Actuate Therapeutics](https://aibio.space/companies/actuate-therapeutics/) ACTU - [Ernexa Therapeutics](https://aibio.space/companies/ernexa-therapeutics/) ERNA - [Beam Therapeutics](https://aibio.space/companies/beam-therapeutics/) BEAM - [Organogenesis Holdings](https://aibio.space/companies/organogenesis/) ORGO ## What Revelation Biosciences does Revelation Biosciences, Inc. is a clinical-stage life science company focused on rebalancing inflammation with Gemini, its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 agonist. Its lead programs focus on kidney disorders. GEM-AKI is being evaluated as a treatment for acute kidney injury, where the text says the only current treatment is supportive care and renal replacement therapy. The company met with the FDA at the end of 2025 and agreed on a single Phase 2/3 adaptive design study with a primary composite endpoint of death and/or dialysis, to support a new drug application. GEM-CKD is being evaluated as a long-term treatment for chronic kidney disease, and the company plans preclinical toxicology studies in 2026 to support a repeat-dose Phase 2 study. The company may also pursue out-licensing and academic collaborations for Gemini in other conditions. Revelation is based in San Diego, California, and its stock is listed on Nasdaq under the ticker REVB. | Product or program | What it is | Stage | |---|---|---| | GEM-AKI (Gemini) | Gemini formulation for acute kidney injury | Phase 2/3 adaptive design study agreed with FDA; to start as soon as feasible | | GEM-CKD (Gemini) | Gemini formulation for chronic kidney disease | Preclinical toxicology studies planned for 2026 before a repeat-dose Phase 2 study | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1810560/000119312526076552/revb-20251231.htm). ## Revelation Biosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$4.1 million](https://www.sec.gov/Archives/edgar/data/1810560/000119312526076552/) | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1810560/000119312526076552/) | | Net income (loss) | [-$8.9 million](https://www.sec.gov/Archives/edgar/data/1810560/000119312526076552/) | [-$15.0 million](https://www.sec.gov/Archives/edgar/data/1810560/000119312526076552/) | | Cash from operations | [-$8.3 million](https://www.sec.gov/Archives/edgar/data/1810560/000119312526076552/) | [-$18.3 million](https://www.sec.gov/Archives/edgar/data/1810560/000119312526076552/) | | Cash and equivalents | [$10.7 million](https://www.sec.gov/Archives/edgar/data/1810560/000119312526337967/) | [$6.5 million](https://www.sec.gov/Archives/edgar/data/1810560/000119312526076552/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $11.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Revelation Biosciences Did Revelation Biosciences do a reverse stock split? Our latest story on this, dated Jan 7, 2025: "Nasdaq panel keeps Revelation Biosciences listed on condition of reverse stock split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasdaq-panel-keeps-revelation-biosciences-listed-condition-reverse/). Has Revelation Biosciences raised money recently? Our latest story on this, dated Sep 15, 2025: "Revelation Biosciences gets $9.6 million gross proceeds in warrant inducement deal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/revelation-biosciences-gets-9-6-million-gross-proceeds-warrant/). Has Revelation Biosciences received a Nasdaq deficiency notice? Our latest story on this, dated Jan 7, 2025: "Nasdaq panel keeps Revelation Biosciences listed on condition of reverse stock split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasdaq-panel-keeps-revelation-biosciences-listed-condition-reverse/). What is the ticker symbol of Revelation Biosciences? Revelation Biosciences, Inc. trades under the ticker REVB on NASDAQ. Where is Revelation Biosciences listed? Revelation Biosciences, Inc. is listed on NASDAQ. What is the SEC CIK of Revelation Biosciences? The SEC Central Index Key (CIK) for Revelation Biosciences, Inc. is 1810560. Its filings are on SEC EDGAR. How many shares does Revelation Biosciences have outstanding? 3,983,416 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Revelation Biosciences listed under? Our directory records Revelation Biosciences, Inc. under United States. What does Revelation Biosciences do? Our directory classifies Revelation Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Revelation Biosciences? The ISIN recorded for Revelation Biosciences, Inc. is US76135L8871. Does aibio.space cover Revelation Biosciences? aibio.space lists Revelation Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Revelation Biosciences incorporated? SEC records list its state or country of incorporation as DE. What does Revelation Biosciences develop? Revelation Biosciences, Inc. is a clinical-stage life science company focused on rebalancing inflammation with Gemini, its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 agonist. Its lead programs focus on kidney disorders. What is GEM-AKI (Gemini) from Revelation Biosciences? GEM-AKI (Gemini): Gemini formulation for acute kidney injury Stage: Phase 2/3 adaptive design study agreed with FDA; to start as soon as feasible. What is GEM-CKD (Gemini) from Revelation Biosciences? GEM-CKD (Gemini): Gemini formulation for chronic kidney disease Stage: Preclinical toxicology studies planned for 2026 before a repeat-dose Phase 2 study. ## Investor discussion: Revelation Biosciences Members talk about Revelation Biosciences (REVB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Revelation Biosciences, newest first. Each line links the filing it comes from. 1. 2026-05-11 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1810560/000119312526215804/2026_annual_meeting_def1.htm) 2. 2026-04-30 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1810560/000119312526196729/2026_annual_meeting_pre1.htm) 3. 2026-01-29 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,3.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1810560/000119312526027742/revb-20260126.htm) 4. 2025-09-15 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1810560/000119312525203750/revb-ex99_1.htm) 5. 2025-07-09 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1810560/000095017025094789/revb-ex99_1.htm) 6. 2025-06-25 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1810560/000095017025089972/revb-ex99_1.htm) 7. 2025-06-09 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1810560/000095017025083815/2025_annual_meeting_def_.htm) 8. 2025-06-04 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1810560/000095017025081604/revb-ex99_1.htm) 9. 2025-05-29 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1810560/000095017025078948/2025_annual_meeting_pre_.htm) 10. 2025-02-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1810560/000095017025025626/revb-ex99_1.htm) 11. 2025-01-30 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1810560/000095017025011197/revb-20250128.htm) 12. 2025-01-21 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1810560/000095017025007303/revb-ex99_1.htm) 13. 2025-01-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1810560/000095017025002828/revb-ex99_1.htm) 14. 2024-12-16 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1810560/000095017024136402/revb-20241213.htm) 15. 2024-12-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1810560/000095017024135895/revb-20241212.htm) 16. 2024-12-05 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1810560/000095017024133661/2024_special_meeting_pre.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:REVB on TradingView](https://www.tradingview.com/symbols/NASDAQ-REVB/). ## SEC filings and registration - **SEC name**: Revelation Biosciences, Inc. - **CIK**: 1810560 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: REVB (Nasdaq), REVBW (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO, CA, 92122 - **Phone**: 650-800-3717 - **Shares outstanding**: 3,983,416 as of 2026-08-03 (10-Q filed 2026-08-06) - **Former names**: Petra Acquisition Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1810560/000119312526357120/revb-20260817.htm) filed 2026-08-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1810560/000119312526338097/revb-20260806.htm) filed 2026-08-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1810560/000119312526337967/revb-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1810560/000119312526302008/revb-20260710.htm) filed 2026-07-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1810560/000119312526281200/revb-20260624.htm) filed 2026-06-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1810560/000119312526251784/revb-20260601.htm) filed 2026-06-01 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1810560/000119312526215804/2026_annual_meeting_def1.htm) filed 2026-05-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1810560/000119312526212064/revb-20260507.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001810560), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Revelation Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker REVB, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Revelation Biosciences, Inc. - **Ticker**: REVB - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US76135L8871 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-REVB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/revelation-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Revelation Biosciences (REVB) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/revelation-biosciences/